Anti-BCMA CAR T Cells Therapy Active in Pretreated Multiple Myeloma

Despite significant advances in the treatment of multiple myeloma (MM) and substantial improvement in survival in the past decade, it remains an incurable disease. Patients with relapsed MM who are double refractory to proteasome inhibitors and immunomodulatory drugs (IMiDs), or who have relapsed after ≥3 prior therapies, have a median survival of 8 months. Chimeric […]

Read More

Combo Improves Outcomes in Waldenström Macroglobulinemia

Adding Ibrutinib to Rituximab Improves PFS Over Rituximab Alone Waldenström macroglobulinemia (WM) is an uncommon plasma-cell disorder, characterized by overproduction of serum immunoglobulin M (IgM). While there is no standard of care for WM, the anti-CD20 monoclonal antibody rituximab is a common treatment for both treatment-naïve and previously treated patients. Furthermore, based on results from […]

Read More

RET Inhibitor LOXO-292 Shows Promise in Phase I Trial

Alterations in the oncogene RET occur in several solid tumors, including non-small cell lung cancer (NSCLC), thyroid cancer, and pancreatic cancer. Unfortunately, previous attempts to target these alterations with multikinase inhibitors have failed. LOXO-292 is a potent and highly selective RET inhibitor that has demonstrated high activity against RET-altered tumors in both in vitro and […]

Read More

FDA Expands Arsenal of Oncology/Hematology Medicines in June

New BRAF/MEK Inhibitor Combo in Melanoma. The Food and Drug Administration (FDA) approved the combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib (Braftovi® and Mektovi®, Array BioPharma Inc) for the treatment of patients with metastatic melanoma with a BRAF V600E or V600K mutation. This approval was based on results from the phase […]

Read More

Low-Dose Maintenance Chemo for High-Risk Rhabdomyosarcoma

For the vast majority of patients with rhabdomyosarcoma, a rare soft-tissue sarcoma occurring more commonly in children, standard therapy comprising of surgery, radiation, and high-dose chemotherapy leads to long-term survival and potential cure. However, for high-risk patients or those who progress on first-line therapy, outcomes are poor. With a cure rate of only 20% to […]

Read More

Pembrolizumab and Chemo Combo New Option for Squamous NSCLC

In recent years immunotherapy with PD-1 inhibitors has become the standard of care for first-line treatment of patients with non-squamous non-small cell lung cancer (nonsq NSCLC) in the absence of targetable driver mutations. For patients with PD-L1 expression >50%, pembrolizumab monotherapy is an approved treatment option for both nonsq and squamous (sq) NSCLC. Based on […]

Read More

Adjuvant mFOLFIRINOX, New Standard of Care for Resectable Pancreatic Cancer

The most common treatment approach for patients with resectable pancreatic cancer is surgery, followed by six cycles of adjuvant chemotherapy with gemcitabine or, more recently, with gemcitabine/capecitabine in combination. Unfortunately, the majority of patients relapse within two years, highlighting a need for improved treatment options for early stage pancreatic cancer. At the 2018 American Society […]

Read More

Clinically Meaningful Progression-Free Survival Benefit With Ribociclib and Fulvestrant in Advanced HR-Positive Breast Cancer

In recent years, cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors have become standard of care in combination with endocrine therapy for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC). Ribociclib is a CDK 4/6 inhibitor that has recently been approved, in combination with an aromatase inhibitor, for first-line […]

Read More

Practice-Changing Results From TAILORx Trial in Early Breast Cancer

For women with node-negative, hormonal receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, early breast cancer, the 21-gene recurrence score (RS) assay can be used to predict risk of recurrence and to tailor treatment. Patients with low RS (0-10) have low risk of recurrence when treated with endocrine therapy alone, while patients with high RS […]

Read More

Upfront Cytoreductive Nephrectomy Not Needed Before Targeted Therapy in mRCC

For patients with metastatic renal cell carcinoma (mRCC), initial treatment typically includes cytoreductive nephrectomy followed by angiogenesis inhibitor therapy. While retrospective analyses have historically shown that patients who receive a nephrectomy have prolonged survival compared to those who do not, no study has directly compared nephrectomy and targeted therapy in patients newly diagnosed with mRCC. […]

Read More